Related Experiment Video
Updated: Jun 12, 2026
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
[Analysis of coagulation factor VIII inhibitor development related factors in hemophilia A patients.]
Lu-Lu Zhang1, Zi-Qiang Yu, Wei Zhang
1The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, The Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, China.
Objective:
To analyze the clinical features of hemophilia A (HA), and the factors associated with the factor VIII (FVIII) inhibitor development.
Methods:
One huandred and thirteen patients with HA were recruited in this retrospective study, among whom, 85 were treated with FVIII replacement therapy. The FVIII inhibitor levels and factors associated with the inhibitor development were correspondingly investigated in these 85 patients.
Results:
FVIII inhibitor developed in 28.24% of the 85 severe and moderate patients treated with FVIII. Factors of statistical significance (P < 0.05) associated with the low-titer FVIII inhibitor development were as follows: the first enduring adminstration of FVIII, the situation of the patients, and the high dose FVIII used in severe bleeding or major operation.
Conclusion:
The development of FVIII inhibitor by Bethesda assay in Chinese hemophilia A patients is not rare, especially that with low-titer. Most of them are severe and moderate patients. The inhibitor development was associated with the following factors: the first adminstration of FVIII for more than 5 days, the severe or moderate conditions of patients, the high dose FVIII used in severe bleeding or major operation.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:20Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:09Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...